<DOC>
	<DOCNO>NCT02789566</DOCNO>
	<brief_summary>The primary objective study provide description pharmacokinetic property primaquine metabolite characterize healthy obese Thai subject . This open-label , single dose pharmacokinetic study 10 healthy obese G6PD normal , subject admit inpatient receive 1 regimen 1 visit .</brief_summary>
	<brief_title>Pharmacokinetic Study Primaquine Healthy Obese Thai Adult Subjects</brief_title>
	<detailed_description>Subjects 1 hospitalization . The visit require hospitalization 24 hour . After screen ( visit 1 ) , subject receive Primaquine ( PQ ) 30 mg base single dose first admission ( visit 2 ) . Assessment safety profile do admission investigate team proceed regimen . The study enroll 10 healthy obese subject ( Body mass index [ BMI ] ≥30 kg/m2 ) male female , age 18-60 year , pharmacokinetic unit Faculty Tropical Medicine , Mahidol University . Participants healthy HIV-1 , hepatitis B C uninfected individual comprehend purpose study provide write consent . Participants screen eligibility base inclusion exclusion criterion . If dos complete without replacement subject , total number subject study 10 . All subject undergo screen assessment within 7 day prior single dose determine eligibility enrollment study .</detailed_description>
	<mesh_term>Primaquine</mesh_term>
	<criteria>1 . Healthy judge responsible physician abnormality identify medical evaluation include medical history physical examination . 2 . Males Females age 18 year 60 year . 3 . BMI ≥ 30 kg/m2 ( BMI= body weight [ BW ] ( kg ) /height ( m2 ) ) 4 . A female eligible enter participate study : childbearing potential , negative serum pregnancy test screen urine pregnancy test prior start study drug period , abstain sexual intercourse agree use effective contraceptive method ( e.g. , intrauterine device , hormonal contraceptive drug , tubal ligation female barrier method spermicide ) study completion followup procedure postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum follicle stimulate hormone level &gt; 40 mIU/mL 6 week postsurgical bilateral oophorectomy without hysterectomy nonchildbearing potential include premenopausal female document ( medical report verification ) hysterectomy double oophorectomy 5 . A male eligible enter participate study : agrees abstain ( use condom ) sexual intercourse female childbearing potential lactating female ; willing use condom/spermicide , study completion followup procedure . 6 . Read , comprehend , write sufficient level complete studyrelated material . 7 . Provide sign dated write informed consent prior study participation . 8 . Normal electrocardiogram ( ECG ) QTc &lt; 450 msec . 9 . Willingness ability comply study protocol duration trial . 1 . Females pregnant , try get pregnant , lactate . 2 . The subject evidence active substance abuse may compromise safety , pharmacokinetics , ability adhere protocol instruction . 3 . A positive prestudy hepatitis B surface antigen , positive hepatitis C antibody , positive human immunodeficiency virus1 ( HIV1 ) antibody result screen . 4 . Subjects personal history cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode , additional risk factor torsades de point ( heart failure , hypokalemia ) . 5 . Subjects family history sudden cardiac death . 6 . A creatinine clearance &lt; 70 mL/min determine Salazar Corcoran equation For men : [ 137 age ] x [ ( 0.285x weight ( kg0 ) + ( 12.1x height ( ) 2 ] / ( 51xSCr ) . For woman ; [ 146 age ] x ( 0.287xweight ( kg ) ) + ( 9.74xheight ( ) 2 ] / ( 60xSCr ) Where age year , weight ( wt ) kg , serum creatinine ( Scr ) unit mg/dL [ Salazar , 1988 ] . 7 . History alcohol substance abuse dependence within 6 month study : History regular alcohol consumption average &gt; 7 drinks/wk woman &gt; 14 drinks/wk men . One drink equivalent 12 g alcohol = 5 oz ( 150 mL ) wine 12 oz ( 360 mL ) beer 1.5 oz ( 45 mL ) 80 proof distil spirit within 6 month screen . 8 . Use prescription nonprescription drug except paracetamol dose 2 grams/day , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication completion followup procedure , unless opinion investigator , medication interfere study procedure compromise subject safety ; investigator take advice manufacturer representative necessary . 9 . The subject participate clinical trial receive drug new chemical entity within 30 day 5 half life , twice duration biological effect drug ( whichever longer ) prior first dose study medication . 10 . The subject unwilling abstain ingest alcohol within 48 hour prior first dose study medication collection final pharmacokinetic sample . 11 . Subjects donate blood extent participation study would result 300 mL blood donate within 30day period . Note : This include plasma donation . 12 . Subjects history allergy study drug drug class , history drug allergy , opinion investigator , contraindicate participation trial . Subjects unstable medical condition , opinion investigator would compromise participation trial . 13 . Subjects unstable medical condition , opinion investigator would compromise participation trial . 14 . Those , opinion investigator , risk noncompliance study procedure . 15 . Lack suitability participation study , reason , opinion investigator . 16 . AST ALT &gt; 1.5 upper limit normal ( ULN ) 17 . Subjects history renal disease , hepatic disease , and/or cholecystectomy 18 . G6PD deficient . 19 . Abnormal methaemoglobin level . ( Normal range 03 % ) 20 . History malaria treatment Primaquine within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Primaquine</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>